Table 1 Demographic data among 33 patients
Demographic data | The studied group (n = 33) | |
|---|---|---|
Gender | ||
Male | 23 (69.7%) | |
Female | 10 (30.3%) | |
Age (Years) | ||
Mean ± SD | 43.12 ± 14.13 | |
Min–Max | 22–71 | |
Age groups | ||
20–< 30 y | 8 (24.2%) | |
30–< 40 y | 8 (24.2%) | |
40–< 50 y | 6 (18.2%) | |
50–< 60 y | 6 (18.2%) | |
> 60 y | 5 (15.2%) | |
Lymphoma types | ||
NHL | 20 (60.6%) | |
HD | 13 (39.4%) | |
Lymphoma subtypes | ||
NHL | ||
DLBCL | 16 (80.0%) | |
Adult T cell | 1 (5.0%) | |
Mantle cell | 1 (5.0%) | |
Peripheral T cell | 1 (5.0%) | |
Lymphoblastic | 1 (5.0%) | |
HD | ||
Mixed cellularity | 7 (53.8%) | |
Nodular sclerosis | 6 (46.2%) | |
Bone marrow biopsy | ||
Positive | 3 (9.1%) | |
Negative | 30 (90.9%) | |
Initial disease stage | ||
I | 1 (3.0%) | |
IE | 7 (21.2%) | |
II | 9 (27.3%) | |
IIE | 1 (3.0%) | |
II bulky | 2 (6.1%) | |
III | 4 (12.1%) | |
IV | 9 (27.3%) | |
Serum LDH | 1 (3.0%) | |
Normal | 17 (51.5%) | |
High | 16 (48.5%) | |
Extra-nodal involvement | ||
None | 18 (54.5%) | |
One site | 10 (30.3%) | |
More than one site | 5 (15.2%) | |
Performance status | ||
0 | 7(21.2%) | |
1 | 16(48.5%) | |
2 | 5(15.2%) | |
3 | 3 (9.1%) | |
4 | 2 (6.1%) | |
International Prognostic Score and Risk Category | ||
0–1 Low risk | 17 (51.5%) | |
2 Low-intermediate risk | 8 (24.2%) | |
3 High-intermediate risk | 6 (18.2%) | |
4–5 High risk | 2 (6.1 %) | |